Phase I Trial From GRID 18F-FDG-PET Biological Imaging-guided Intensitymodulated Radiotherapy (BG-IMRT) With Patients With Recurrent or New Head or Neck Tumor in Previously Radiated Area
This trial is active, not recruiting.
|Condition||head and neck tumors|
|Sponsor||University Hospital, Ghent|
|Start date||February 2007|
|End date||September 2015|
|Trial size||12 participants|
|Trial identifier||NCT00528294, 2007/010|
This trials examines the feasibility of GRID-therapy combined with biologically imaging based IMRT (BG-IMRT). Within this trial, the strict toxicity parameters of primary treatment of head and neck tumors are used. The GRID and BG-IMRT technique might be possible to reduce the total radiation dose 2 to 3 times.
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
GRID-radiotherapy followed by biological imaging guided IMRT
Maximum tolerated dose.
time frame: 3 months after end of treatment
Superior local control with Grid 18F-FDG-PET BG-IMRT using previously obtained maximum tolerated dose.
time frame: 1 year.
Male or female participants at least 18 years old.
Inclusion Criteria: - Recurrent or new head or neck tumor - 18 years or older
|Official title||Phase I Trial From GRID 18F-FDG-PET Biological Imaging-guided Intensitymodulated Radiotherapy (BG-IMRT) With Patients With Recurrent or New Head or Neck Tumor in Previously Radiated Area|
|Principal investigator||Wilfried De Neve, MD, PhD|
Call for more information